TScan Therapeutics (TCRX) Competitors $1.44 -0.02 (-1.37%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.08%) As of 06/20/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. ACB, OCGN, ZYBT, ATXS, ADCT, CMPX, AURA, IVA, HRTX, and RCKTShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Aurora Cannabis (ACB), Ocugen (OCGN), Zhengye Biotechnology (ZYBT), Astria Therapeutics (ATXS), ADC Therapeutics (ADCT), Compass Therapeutics (CMPX), Aura Biosciences (AURA), Inventiva (IVA), Heron Therapeutics (HRTX), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Aurora Cannabis Ocugen Zhengye Biotechnology Astria Therapeutics ADC Therapeutics Compass Therapeutics Aura Biosciences Inventiva Heron Therapeutics Rocket Pharmaceuticals TScan Therapeutics (NASDAQ:TCRX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Does the MarketBeat Community prefer TCRX or ACB? Aurora Cannabis received 341 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 82.69% of users gave TScan Therapeutics an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformTScan TherapeuticsOutperform Votes4382.69% Underperform Votes917.31%Aurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% Do analysts prefer TCRX or ACB? TScan Therapeutics currently has a consensus price target of $7.80, indicating a potential upside of 441.67%. Given TScan Therapeutics' higher probable upside, research analysts clearly believe TScan Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Which has more risk and volatility, TCRX or ACB? TScan Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Which has better earnings and valuation, TCRX or ACB? Aurora Cannabis has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M28.90-$127.50M-$1.09-1.32Aurora Cannabis$246.72M0.93$1.63M$0.1137.09 Is TCRX or ACB more profitable? Aurora Cannabis has a net margin of 1.32% compared to TScan Therapeutics' net margin of -2,974.08%. Aurora Cannabis' return on equity of 0.13% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-2,974.08% -55.76% -36.56% Aurora Cannabis 1.32%0.13%0.10% Does the media prefer TCRX or ACB? In the previous week, Aurora Cannabis had 16 more articles in the media than TScan Therapeutics. MarketBeat recorded 16 mentions for Aurora Cannabis and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.21 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TScan Therapeutics Neutral Aurora Cannabis Neutral Do insiders and institutionals hold more shares of TCRX or ACB? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 4.4% of TScan Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAurora Cannabis beats TScan Therapeutics on 12 of the 19 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.49M$2.81B$5.16B$8.53BDividend YieldN/A2.69%5.38%4.21%P/E Ratio-1.3221.3325.8119.17Price / Sales28.90302.62410.78110.15Price / CashN/A40.9225.4426.73Price / Book0.347.427.925.78Net Income-$127.50M-$55.10M$3.15B$248.44M7 Day Performance-5.88%-2.51%-0.69%-0.29%1 Month Performance4.35%6.09%4.55%3.92%1 Year Performance-77.85%-1.66%41.88%15.59% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics3.3088 of 5 stars$1.44-1.4%$7.80+441.7%-77.8%$81.49M$2.82M-1.32100ACBAurora Cannabis0.2335 of 5 stars$6.15+5.1%N/A-19.8%$345.72M$320.81M123.021,340Earnings ReportGap DownOCGNOcugen1.2021 of 5 stars$1.16+2.7%$6.00+417.2%-20.3%$338.76M$4.52M-6.4480ZYBTZhengye BiotechnologyN/A$7.18+13.2%N/AN/A$338.65M$189.75M0.00278Positive NewsGap DownATXSAstria Therapeutics1.9188 of 5 stars$5.93+3.7%$30.00+405.9%-37.9%$334.65MN/A-2.8430ADCTADC Therapeutics2.5888 of 5 stars$3.37-5.8%$8.50+151.9%+4.3%$334.63M$75.82M-1.41310Analyst UpgradeHigh Trading VolumeCMPXCompass Therapeutics3.4433 of 5 stars$2.37-1.7%$13.13+453.8%+118.2%$327.73M$850K-6.4120Positive NewsGap UpAURAAura Biosciences1.6039 of 5 stars$6.40-0.3%$22.00+243.8%-16.1%$321.72MN/A-3.7050IVAInventiva2.0744 of 5 stars$3.36-3.2%$10.40+209.5%+23.2%$321.42M$9.20M0.00100Gap DownHRTXHeron Therapeutics3.8658 of 5 stars$2.03+5.2%$5.00+146.3%-38.1%$309.71M$148.52M-11.28300RCKTRocket Pharmaceuticals4.9197 of 5 stars$2.88-1.7%$19.57+579.6%-88.0%$307.54MN/A-1.05240Trending News Related Companies and Tools Related Companies Aurora Cannabis Competitors Ocugen Competitors Zhengye Biotechnology Competitors Astria Therapeutics Competitors ADC Therapeutics Competitors Compass Therapeutics Competitors Aura Biosciences Competitors Inventiva Competitors Heron Therapeutics Competitors Rocket Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRX Stock Free TCRX Stock Alerts